Photocure fundamentale forhold (PHO)

[TekBot]

Photocure Partner Asieris announces coverage of Hexvix by the Lecheng Global Specialty Drug Insurance

Press release - Oslo, Norway, September 15, 2022: Photocure ASA (PHO: OSE), The
Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE:
688176) has communicated today on the inclusion of Hexvix[®] in the 2022 edition
…

Vis børsmeldingen

of the Lecheng Global Specialty Drug Insurance Specialty Drug List.

As a new specialty drug benefit plan developed under the guidance of the
government covering 40 domestic specialty drugs and 60 overseas specialty drugs,
the Lecheng Global Specialty Drug Insurance allows Hainan citizens access to
more advanced medical resources and comprehensive coverage of their medical
needs.

In December 2021, Hexvix received initial clinical use in the Boao Lecheng
International Medical Tourism Pilot Zone in Hainan Province when the first
prescription in China was issued at Hainan General Hospital, and the first
patient procedure was completed. Asieris received approval from the National
Medical Products Administration (NMPA) for Hexvix to be included in phase III
clinical trials in the first quarter of 2022 as well as a real-world clinical
data pilot study.

Asieris expects the incorporation of Hexvix into the Lecheng Global Specialty
Drug Insurance to help them explore innovative access models, so that innovative
drugs can be introduced into China and covered by commercial insurance earlier
and faster.

Read Asieris’ full media release here: Hexvix®, A Diagnostic Drug of Asieris, is
Now Covered by the 2022 Lecheng Global Specialty Drug Insurance - Asieris
Pharmaceuticals (https://asieris.com/hexvix-a-diagnostic-drug-of-asieris-is-now
-covered-by-the-2022-lecheng-global-specialty-drug-insurance/)

Note to editors

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview[ ]improves the detection of tumors and leads to more
complete resection, fewer residual tumors and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe, and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Isreal. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[TekBot]

New study demonstrates that tumor removal in the outpatient setting is as good as TURBT under general anesthesia

Press release - Oslo, Norway, September 20th, 2022: Photocure ASA, The Bladder
Cancer Company, announces the publication of first results from the Laser III
clinical study in the medical journal, European Urology. The study is part of a
…

Vis børsmeldingen

systematic program aimed at verifying the safe treatment of bladder tumors in
the outpatient setting. Laser III results demonstrate the non-inferiority of
outpatient laser-mediated destruction of bladder tumors in conjunction with blue
light cystoscopy (BLC[®]) and Hexvix[®] versus inpatient BLC TURBT* under
general anesthesia. Photocure has supported this program and the specific study
since 2016.

Laser III is a prospective, randomized, non-inferiority trial conducted in the
Capital Region of Denmark from 2016 to 2020 (NCT02886026). Patients with
histologically verified Ta low-grade bladder tumor recurrence were enrolled. A
total of 206 patients were randomized; 176 finished treatment and were available
for follow-up as per protocol. The first results, now published in European
Urology, evaluated 4-month non-inferiority of outpatient laser-mediated ablation
of recurrent Ta tumors with flexible cystoscopes under local anesthesia,
compared to TURBT under general anesthesia. Both the out-patient laser procedure
and TURBT procedure were performed under BLC-guidance. Four-month recurrence
-free survival was assessed as the primary endpoint with a predefined non
-inferiority criterion of 15%. Secondary outcome measures were pain during the
outpatient laser ablation, postoperative morbidity, postoperative complications,
and patient’s preference. The 12-month follow-up results are expected to be
presented in a second paper.
Four-month recurrence-free survival was 8% higher after laser-ablation of the
bladder tumor compared to TURBT, and the predefined noninferiority criterion was
met. The study authors conclude that laser intervention in the outpatient
setting is as good as TURBT with general anesthesia, and has less complications.

In addition, the paper also advocates the importance of enhanced cystoscopy to
mediate this practice change. As recommended by the guidelines, enhanced
cystoscopy should be used during surgical treatment of non-muscle invasive
bladder cancer to improve detection and reduce recurrence.

“The study outcomes clearly demonstrate that for patients with small low grade
stage Ta bladder tumors the procedure can be safely moved from the OR to the
office, thereby reducing the burden for patients stemming from general
anesthesia and cost related to hospital stays. Safety is the most important term
here. Our team find that blue light cystoscopy with Hexvix in the OPD support
the identification of small bladder tumors which therefore safely can be removed
with laser before they become too large for outpatient treatment.” said Dr.
Gregers G Hermann, the Lead Investigator of this study and Consultant Urologist,
MD, DM Sc, F.E.B.U., Dept. of Urology, Herlev/Gentofte hospital, Denmark.

“We expect to see more scientific studies investigating how some of the more
intensive procedures like TURBTs can be reduced, avoided, or made more bearable
for patients. In non-muscle-invasive bladder cancer especially, where most
patients are over 55 years old, research into reducing patient burden is of
great importance. We believe BLC with Hexvix/Cysview can help responsible
researchers in these efforts by minimizing the concern of uncertainty when it
comes to detecting the tumors,” said Dan Schneider, President and CEO of
Photocure.

Read the full publication here:
Outpatient Photodynamic Diagnosis–guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis–guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial - ScienceDirect

(Clinicaltrials.gov Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors - Full Text View - ClinicalTrials.gov)

*TURBT: Transurethral resection of bladder tumor

Note to editors

Hexvix[®]/Cysview[®] and BLC[®] are registered trademarks of Photocure ASA.

This press release may contain product details and information which are not
valid, or a product that is not accessible, in your country. Please be aware
that Photocure does not take any responsibility for accessing such information,
which may not comply with any legal process, regulation, registration, or usage
in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[CanonBoy]

Denne var veldig positiv for flex og fremtidig bruk og utbredelse av systemet. Å behandle pasienter uten innleggelse på sykehus og ekstra bedøvelse vil være mye mer effektivt og kostnadsbesparende. Det må selvsagt gjennomføres flere studier, men dette lover godt for FBLC og utbredelse til mindre klinikker.

“The study outcomes clearly demonstrate that for patients with small low grade
stage Ta bladder tumors the procedure can be safely moved from the OR to the
office, thereby reducing the burden for patients stemming from general
anesthesia and cost related to hospital stays. Safety is the most important term
here. Our team find that blue light cystoscopy with Hexvix in the OPD support
the identification of small bladder tumors which therefore safely can be removed
with laser before they become too large for outpatient treatment.” said Dr.
Gregers G Hermann"

“Four-month recurrence-free survival was 8% higher after laser-ablation of the
bladder tumor compared to TURBT, and the predefined noninferiority criterion was
met. The study authors conclude that laser intervention in the outpatient
setting is as good as TURBT with general anesthesia, and has less complications.”

[TekBot]

Photocure ASA – Major shareholding disclosure

On 23 September 2022, Briarwood Chase Management LLC, via a private investment fund under its management, acquired 92,704 shares in Photocure ASA. Following which, Briarwood Chase Management LLC controls 4,113,097 shares in Photocure ASA, corresponding to 15.17% of the company’s outstanding share capital and voting rights. The shares in Photocure ASA are held through a private investment fund which is managed by Briarwood Chase Management LLC, whose Managing Member is Aalap Mahadevia.

This notification is made public pursuant to section 4-2 of the Norwegian Securities Trading Act.
…

Vis børsmeldingen

Kilde

[TekBot]

Photocure Announces the Commercial Availability of Karl Storz’s New Blue Light System in the U.S.

Karl Storz and Photocure to collaborate on commercializing the high-definition
system

…

Vis børsmeldingen

Press Release - Oslo, Norway, September 28, 2022: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces the commercial availability of Karl Storz’s
New Blue Light equipment powered by SaphiraT in the U.S. As part of the rollout,
Karl Storz plans to host a Virtual Launch event for the medical community
streamed from its El Segundo, California office where Sia Daneshmand M.D. and
Kristin Scarpato M.D. M.P.H. will discuss the clinical benefits of using BLC[®]
with Cysview[® ]for NBMIC*, while sharing their perspectives on the advantages
that the New Blue Light system provides over the original system for TURBT**.
The Virtual Launch event is scheduled to take place on October 13, 2022 at
4:00pm Pacific Time.

“We are pleased to share that Karl Storz has begun filling Obsolescence
Protection Program (OPP) orders for customers who purchased New Blue Light
system upgrades last year,” said Geoff Coy, Vice President and General Manager,
North America. “Orders for the new Saphira system appear to be outpacing orders
from the past signaling pent up demand for the advanced technology, and we
expect to begin filling new account orders in the fourth quarter. Given the
strong demand, we continue to believe that BLC is on its way to becoming the
standard of care for endoscopic visualization of bladder cancer.”

“Uro-oncologists and their staff have expressed a strong desire to have the new
Blue Light system at their hospitals, and the upcoming Virtual Launch Event is
an opportunity to showcase the system’s benefits and broaden awareness of BLC in
the market,” said Ken Pugh, Head of North America Marketing and Alliance
Management. “Accordingly, we are working diligently with our partners to ensure
that all customers who want The New Blue Light, have it for all appropriate
patients with NMIBC.”

Dr. Sia Daneshmand, M.D., is Professor of Urology with Clinical Scholar
designation and serves as director of clinical research as well as the urologic
oncology (SUO) fellowship director at the University of Southern California
(USC) in Los Angeles.
Dr. Kristin Scarpato, M.D., M.P.H., is Associate Professor Department of Urology
residency program director and vice chair of education for the Department of
Urology, Division of Urologic Oncology at Vanderbilt University Medical Center
in Tennessee.

*NMIBC: Non-muscle invasive bladder cancer

**TURBT: Transurethral resection of bladder tumor

Note to editors:

Hexvix[®]/Cysview[®] and BLC[®] are registered trademarks of Photocure ASA.
IMAGE1 ST and SaphiraT are registered trademarks of KARL STORZ Endoscopy.

This press release may contain product details and information which are not
valid, or a product that is not accessible, in your country. Please be aware
that Photocure does not take any responsibility for accessing such information,
which may not comply with any legal process, regulation, registration, or usage
in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022]
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Savepig (101 likes)

@Savepig

Vi er vel mer eller mindre ferdigdebattert om ultimovacs i denne tråden…

2. @Rodjer (64 likes)

@Rodjer

Ny klinikk oppført på Cysview.

3. @myk (61 likes)

@myk

Eneste som betyr noe er top linje veksten, kostnadene blir konstante fremover i forhold til veksten som kommer. Slapp av dette blir bra og kjøp.

Resten av topp 10:

4. @rosk82 (57 likes)

5. @Hayen (44 likes)

6. @Snoeffelen (38 likes)

7. @kreinh (26 likes)

8. @Bingo123 (23 likes)

9. @Quadruple (22 likes)

10. @nordpolen (20 likes)

Gratulerer!

[GrevenAvGral]

@TekBot må på jobb, børsmelding på SEB over 5%

[TekBot]

Photocure ASA: Invitation to presentation of third quarter 2022 financial results

Oslo, Norway, 25 October 2022: Photocure ASA (Photocure, PHO: OSE) will announce
the third quarter 2022 financial results on Wednesday 2 November 2022 at 08:00
CEST and will present a live webcast at 14:00 CEST the same day.
…

Vis børsmeldingen

The quarterly report and presentation will be published at 08:00 CEST and will
be publicly available at www.photocure.com.

The investor presentation will be streamed live and be hosted by Daniel
Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and
questions can be submitted throughout the event. The presentation is scheduled
to conclude at 14:45 CEST.

The streaming event is available through
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20221102_7.

For further information, please contact:

Photocure
Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway) Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Rodjer (91 likes)

@Rodjer

Ny klinikk oppført på Cysview.

2. @Savepig (90 likes)

@Savepig

Helt entydig feedback fra medlemmene her at det ikke ønskes at spam fra HO dupliseres over til denne tråden, har derfor ryddet en del.

3. @rosk82 (64 likes)

@rosk82

Og hva ville poenget være med det??

Resten av topp 10:

4. @myk (57 likes)

5. @Hayen (55 likes)

6. @Snoeffelen (50 likes)

7. @Quadruple (21 likes)

8. @solskimm (21 likes)

9. @nordpolen (20 likes)

10. @Bingo123 (20 likes)

Gratulerer!

[TekBot]

Photocure ASA: Results for the third quarter of 2022

Oslo, Norway, 2 November 2022: Photocure ASA (OSE:PHO) today reported
Hexvix[®]/Cysview[®] revenues of NOK 96.9 million in the third quarter of 2022,
up 12% compared to Q3 2021 (NOK 86.7 million), and positive EBITDA of NOK 4.7
…

Vis børsmeldingen

million (NOK -0.2 million) for the Company. With the launch of Karl Storz’s new
high-definition blue light system in the U.S., Photocure expects that placements
of new blue light rigid towers will begin to accelerate in the fourth quarter of
this year. A recent ruling by the Centers for Medicare and Medicaid Services
(CMS) improves U.S. reimbursement for Cysview, expanding access in the
Ambulatory Surgery Center (ASC) segment.

“Photocure delivered Hexvix/Cysview revenue growth of 12%, driven by higher unit
sales in both North America and Europe in addition to the net favorable effect
of foreign exchange. I am very pleased to report that our North American
business segment achieved the highest quarterly unit sales volume in our
history, and we are now in a strong position to significantly expand the
installed base of blue light capital equipment in the U.S. and get back to the
high growth trajectory that we were achieving before the pandemic,” says Daniel
Schneider, President & Chief Executive Officer of Photocure.

Photocure reported total group revenues of NOK 106.8 million in the third
quarter of 2022 (NOK 87.4 million), and EBITDA* of NOK 4.7 million (NOK -0.2
million), driven by the increase in product revenue and a milestone payment from
Asieris. Hexvix/Cysview revenues ended at NOK 96.9 million in the quarter (Q3
2021: NOK 86.7 million), due to higher unit sales in both North America and
Europe, and net favorable foreign exchange. EBIT was NOK -1.4 million (-6.3
million) and the cash balance at the end of Q3 2022 was NOK 283.9 million.

Photocure announced the commercial availability of Karl Storz’s new high
-definition blue light rigid system in the United States late in the quarter.
The Company reports that 10 new blue light towers were installed during the
period; 6 new SaphiraT cystoscopes and 4 flexible units. The installed base of
blue light cystoscopes in the U.S. was 339 (302) at the end of the third
quarter, a 12% increase from the same period last year. This includes 62
flexible cystoscopes, an increase of 38%.

“The pipeline for new blue light cystoscopy towers remains stronger than ever.
With the new system now officially launched, we are currently assisting Karl
Storz with the placement and activation of towers for accounts that participated
in the obsolescence protection program to replace the old standard definition
system. We anticipate broader installations of rigid BLC equipment in new
accounts this quarter,” Schneider adds.

With the launch of Karl Storz’s new high-definition blue light system in the
U.S. at the end of the third quarter 2022, Photocure expects that placements of
new blue light rigid towers will accelerate in the fourth quarter of this year
and beyond. Additionally, the post-period ruling by CMS to improve Medicare
reimbursement is anticipated to help increase sales in the Hospital-Based
Outpatient Department (HOPD) setting and enable Photocure’s U.S. commercial team
to penetrate accounts in the ASC site of care.

“With account access now open in our major markets, Karl Storz’s new blue light
system launching, and an improvement in Medicare access and reimbursement
expected to take effect January 1 of next year, I believe that Photocure’s
business is at an inflection point. We remain focused on positioning the
Hexvix/Cysview franchise as the standard of care in the management of bladder
cancer,” Schneider concludes.

Please find the full financial report and presentation enclosed.

EBITDA* and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
third quarter 2022 financial report on page 22.

The quarterly report and presentation will be published at 08:00 CET and will be
publicly available at www.photocure.com. Daniel Schneider, CEO and Erik Dahl,
CFO, will host a live webcast at 14:00 CET.

The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20221102_7

The presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

David Moskowitz
Vice President of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Tolv Hillestad, Group Controller, Photocure ASA,
on 2 November 2022 at 08:00 CET.

Kilde

[TekBot]

Major shareholder disclosure in Photocure ASA

Please see attachment on www.newsweb.no
…

Vis børsmeldingen

Kilde

[Bingo123]

SEB solgte seg litt ned?

[myk]

Ja ser det men skjønner det ikke for SEB til sammen har mye mer enn 5%. Det må være en konto som er redusert til 4,99%.

[TekBot]

Photocure Partner Asieris announces 1[st] Patient enrolled in Hexvix Phase III trial in China

Press Release - Oslo, Norway, November 4, 2022: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE:
688176) has communicated today on the treatment of the first patient in the
…

Vis børsmeldingen

Hexvix[®] phase III bridging trial.

The objective of the multicenter Phase III trial is to achieve regulatory
approval of Hexvix in Mainland China for use in patients with bladder cancer, by
investigating the detection rate and safety of Hexvix and blue light cystoscopy
(BLC[®]) versus white light cystoscopy in patients with non-muscle invasive
bladder cancer (NMIBC). The bridging trial is intended to confirm results from
prior clinical trials in a Chinese population. The clinical trial protocol
follows the protocols for registration studies in countries where Hexvix already
has market authorization. This study will be led by Peking Union Medical College
Hospital and the Chinese Academy of Medical Sciences.

In January 2021, Asieris entered into a license agreement with Photocure ASA to
obtain the exclusive registration and commercialization rights of Hexvix in
mainland China and Taiwan.

On December 26, 2021, Hexvix obtained initial clinical use in the Boao Lecheng
International Medical Tourism Pilot Zone in Hainan Province, when the first
patient received blue light cystoscopy with Hexvix at the Hainan General
Hospital. The phase III clinical trial obtained approval from the National
Medical Products Administration (NMPA) in the first quarter of 2022 and Hexvix
was subsequently included in the real-world clinical data pilot program.

Read Asieris’ full media release here: https://asieris.com/hexvix-a-diagnostic
-drug-for-bladder-cancer-of-asieris-completed-the-first-patient-dose-in-phase
-iii-trial/

The trial is registered here: Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer - Full Text View - ClinicalTrials.gov

Note to editors:

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: Global Cancer Observatory, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[TekBot]

Photocure: CMS improves Medicare reimbursement for Blue Light Cystoscopy with Cysview and expands access in the surveillance setting

Oslo, Norway, November 7, 2022: Photocure ASA., (OSE: PHO), announces that The
United States Centers for Medicare & Medicaid Services (CMS) has released final
payment rates in connection with the recently approved Medicare reimbursement
…

Vis børsmeldingen

changes for Blue Light Cystoscopy (BLC[®]) with Cysview[®] in the hospital
outpatient (HOPD) and ambulatory surgical center (ASC) sites of care. The new
complexity adjustments and resulting increase in payment provide an opportunity
to increase BLC usage in outpatient bladder cancer surveillance procedures.

Link to the CMS Rule: https://www.cms.gov/files/document/cy2023-hospital
-outpatient-prospective-payment-system-and-ambulatory-surgical-center-final
-rule.pdf

CMS confirmed that a complexity adjustment will be available for procedures
billed under CPT Code 52000, as well as CPT Code 52204 which were subject to the
adjustment in 2022. The two procedures, if also billed with the A9589 Code for
Cysview[®] and the C9738 Code for the complexity adjustment, will have higher
reimbursement beginning January 1, 2023.

In the HOPD setting, CMS for the first time has made a complexity adjustment for
CPT 52000 (cystoscopy) and will maintain the current adjustment for CPT 52204
(cystoscopy + biopsy). The new Medicare reimbursement changes increase payment
from $587.56 to $1,854.88 for CPT 52000 (cystoscopy) and from $3,140.04 to
$3,205.12 for CPT 52204 (cystoscopy + biopsy) in the HOPD site of care.

Additionally, CMS for the first time has made a complexity adjustment available
for ASC sites of care for both CPT 52000 and CPT 52204. To facilitate this, CMS
has created two new complexity adjustment C codes for BLC to be used in the ASC
place of service (C7554 with CPT 52000 and C7550 with CPT 52204). The changes
will increase payment beginning in January 2023 from $297.97 to $848.03 for CPT
52000 and from $816.76 to $1,496.56 for CPT 52204.

“The effectiveness and benefits of using Blue Light Cystoscopy with Cysview for
improved detection and management of bladder cancer are widely recognized, and
Photocure has long advocated that CMS provide appropriate reimbursement for BLC
treatment” said Dan Schneider, President and Chief Executive Officer of
Photocure ASA. “We are pleased that CMS has expanded the complexity adjustment
for Cysview in the hospital outpatient setting and will implement a complexity
adjustment for the first time in the ASC site of care. The improved
reimbursement is expected to increase patient access to blue light cystoscopy in
the surveillance setting.”

Note to editors

Hexvix[®]/Cysview[®] and BLC[®] are registered trademarks of Photocure ASA.

This press release may contain product details and information which are not
valid, or a product that is not accessible, in your country. Please be aware
that Photocure does not take any responsibility for accessing such information,
which may not comply with any legal process, regulation, registration, or usage
in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[TekBot]

Major shareholder disclosure

Please see attachment on www.newsweb.no
…

Vis børsmeldingen

Kilde

[Bingo123]

SEB over 5% igjen.

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Rodjer (79 likes)

@Rodjer

Ny klinikk på Cysview

2. @Snoeffelen (62 likes)

@Snoeffelen

Strålende refusjonsmelding på morgenkvisten da.

3. @Hayen (59 likes)

[quote=“Hayen, post:6944, topic:18877”]

@myk

Resten av topp 10:

4. @myk (54 likes)

5. @Savepig (54 likes)

6. @rosk82 (38 likes)

7. @kreinh (36 likes)

8. @solskimm (28 likes)

9. @nordpolen (20 likes)

10. @Meisen (12 likes)

Gratulerer!

[TekBot]

New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting

Press release - Oslo, Norway, December 5th, 2022: Photocure ASA, The Bladder
Cancer Company, announces that new evidence was presented at the 22[nd] Annual
Society of Urologic Oncology (SUO) Meeting demonstrating that Blue Light
…

Vis børsmeldingen

Cystoscopy (BLC[®]) decreases the risk and prolongs time to recurrence based on
Real World Evidence from the U.S. multi-institutional Blue Light Cystoscopy with
Cysview[®] Registry database.

This large, prospective, longitudinal, multisite registry collects data on
NMIBC* patients who have undergone transurethral resection of bladder tumor
(TURBT) using Blue Light as an adjunct to white light cystoscopy (WLC). The new
data represent an interim analysis of the study, which is projected to enroll
4,400 patients in total. In this study, all registry patients analyzed (n=2055)
received Blue Light. They were directly compared to a historical White-Light
(WL)-only control group (n=261) of similar age, stage, grade, and clinical
management (i.e., intravesical therapy).

Kaplan-Meier curves demonstrate recurrence-free survival (RFS) for BLC patients
compared to a WL-only arm with a mean follow up of 27.4 months for BLC and 53
months for the historical WL control arm. The overall risk of recurrence was
significantly lower following BLC compared to WLC alone (Hazard Ratio (HR) 0.33;
95% Confidence Interval (CI) 0.28-0.40, p-value=0<.0001). Authors indicate that
the lower incidence of recurrence in the BLC arm were durable, as rates tracked
over 5 years consistently out-performed WLC in the historical control group.

The data were presented at the Annual Meeting of the Society of Urologic
Oncology meeting held November 30 - December 2, 2022, in San Diego, USA. The SUO
is a congress led by internationally renowned urologic oncologists, medical
oncologists, and scientists on topics of genitourinary medicine such as bladder,
kidney, and prostate cancer. This year, Photocure has continued to partner with
KARL STORZ with a joint exhibit featuring the new blue light SAPHIRAT system, as
well as information on flexible blue light.

“These real-world data from our U.S. Cysview Registry emphasize that better
tumor detection and more complete resection using BLC can translate into more
favorable long-term patient outcomes,” said Geoff Coy Vice President and General
Manager, North America. “Interest in integrating BLC into the management of
bladder cancer is high among practicing urologists, and many stopped by the
exhibit at SUO to see the SAPHIRA demonstration unit on display and get hands-on
experience with the upgraded system for TURBT procedures. SAPHIRA became
commercially available in late September 2022, and we believe that the new
system is helping to expand the use of BLC so that more patients diagnosed with
bladder cancer have access to the benefits of enhanced cystoscopy.”

Read the abstract here: https://suo-abstracts.secure
-platform.com/a/gallery/rounds/15/details/2721

*NMIBC: non-muscle-invasive bladder cancer

Note to editors

Hexvix[®]/Cysview[®] and BLC[®] are registered trademarks of Photocure ASA.
SaphiraT is a registered trademark of KARL STORZ Endoscopy.

This press release may contain product details and information which are not
valid, or a product that is not accessible, in your country. Please be aware
that Photocure does not take any responsibility for accessing such information,
which may not comply with any legal process, regulation, registration, or usage
in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[kreinh]

Oslo, Norway, 5th December 2022, Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in the 7th Annual Nordic American Life Science Conference and in the DNB 13th Annual Healthcare conference in December 2022

https://photocure.com/news/photocure-to-participate-in-the-nalsc-and-dnb-healthcare-conferences-in-december-96